

USP14 Activation Kit



Cat. No. 67-0014-001
Lot. No. 30204

Storage: -70°C

FOR RESEARCH USE ONLY

NOT FOR USE IN HUMANS

PRODUCT DESCRIPTION Page 1 of 2

Kit Utility

The USP14 Activation Kit contains USP14 [6His-tagged] and 26S Proteasome [Ubiquitin-Vinyl Sulfone (Ub-VS) treated] plus sufficient 5x DUB Assay Buffer for preparing the assays. Through the addition of your own DUB substrate of interest, for example Ubiquitin-Rhodamine 110 (Cat# 60-0117-050), you can determine the optimal ratio of USP14:26S Proteasome [Ub-VS treated] appropriate for your assay. (Note: USP14 has no detectable catalytic activity in the absence of activation by the Ub-VS treated 26S Proteasome preparation provided. See Background for more information.)

Once your preferred USP14 activation ratio has been determined, an application of the USP14 Activation Kit that might be of greatest interest is to test for inhibitors of the interaction of USP14 with the proteasome. Experiments may include pre-incubating the test compound(s) with USP14 and/or the 26S Proteasome [Ub-VS treated] prior to mixing.

Background

Deconjugating enzymes (DCEs) are proteases that process ubiquitin or ubiquitin-like gene products, reverse the modification of proteins by a single ubiquitin or ubiquitin-like protein (UBL) and remodel polyubiquitin (or poly-UBL) chains on target proteins (Reyes-Turcu, *et al.*, 2009). The deubiquitylating – or deubiquitinating – enzymes (DUBs) represent the largest family of DCEs and regulate ubiquitin

Continued on page 2

Components

Product	Amount	Cat. No.
USP14 [6His-tagged]	5 µg	64-0018-005
26S Proteasome [Ub-VS treated]	10 µg	65-1020-010
5x DUB Assay Buffer	0.5 ml	64-2001-500

For further information on the deconjugating enzyme or the 26S Proteasome supplied in this kit please refer to the Ubiquigent website: www.ubiquigent.com.

Physical Characteristics

USP14 [6His-tagged]

Species: human

Source: *E. coli*

Quantity: 5 µg

Concentration: 0.5 mg/ml

Formulation: 50 mM HEPES pH 7.5, 150 mM sodium chloride, 2 mM dithiothreitol, 10% glycerol

Molecular Weight: ~58.5 kDa

Purity: >56% by InstantBlue™ SDS-PAGE

Stability/Storage: 12 months at -70°C; aliquot as required

26S Proteasome [Ub-VS treated]

Species: human

Source: transformed HEK293 cells

Quantity: 10 µg

Concentration: 0.2 mg/ml

Formulation: 50 mM Tris/HCl pH 7.4, 10% glycerol, 1 mM ATP

Molecular Weight: ~2500 kDa

Stability/Storage: 12 months at -70°C; Avoid multiple freeze/thaw cycles.

Protocol

For guidance: The ratio used in Ubiquigent's pre-formulated product USP14+26S Proteasome [Ub-VS-treated] (Cat# 64-1010-096) is 20 nM USP14:1.25 nM 26S Proteasome [Ub-VS treated]. Lee *et al.* (2010) used 4 nM USP14:1 nM 26S Proteasome [Ub-VS treated].

1. Prepare sufficient 1x DUB Assay Buffer using the 5x DUB Assay Buffer stock (Cat# 64-2001-500).
2. Prepare a 20 µl reaction per well using the enzyme and proteasome reagents provided, your test compound (if required) and your substrate of choice made up to 20 µl with 1x DUB Assay Buffer.
3. Incubate for 40 min at room temperature.
4. Analyse samples appropriately according to substrate choice.



www.ubiquigent.com
Dundee, Scotland, UK

ORDERS / SALES SUPPORT

International: +1-617-245-0020
US Toll-Free: 1-888-4E1E2E3 (1-888-431-3233)
Email: sales.support@ubiquigent.com

UK HQ and TECHNICAL SUPPORT

International: +44 (0) 1382 381147 (9AM-5PM UTC)
US/Canada: +1-617-245-0020 (9AM-5PM UTC)
Email: tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services.

© Ubiquigent 2014. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0

USP14 Activation Kit



Cat. No. 67-0014-001
Lot. No. 30204

Storage: -70°C

FOR RESEARCH USE ONLY

NOT FOR USE IN HUMANS

PRODUCT DESCRIPTION Page 2 of 2

Continued from page 1

dependent signalling pathways. The activities of the DUBs include the generation of free ubiquitin from precursor molecules, the recycling of ubiquitin following substrate degradation to maintain cellular ubiquitin homeostasis and the removal of ubiquitin or ubiquitin-like proteins (UBL) modifications through chain editing to rescue proteins from proteasomal degradation or to influence cell signalling events (Komander, *et al.*, 2009). There are two main classes of DUB, cysteine proteases and metalloproteases. Ubiquitin specific protease 14 (USP14) is a member of the cysteine protease enzyme family and cloning of the gene was first described by Deshpande *et al.* (1996).

The ubiquitin–proteasome system (UPS) targets selected proteins for degradation by the 26S proteasome. The initial steps in this pathway generate proteins that are covalently tagged with a polyubiquitin chain that is then recognized by ubiquitin receptors of the 26S proteasome. This is a large complex composed of a 20S catalytic core particle and two 19S regulatory particles (Kok, *et al.*, 1993) that catalyse the final step in the pathway. While the 20S particle is composed of a catalytic chamber for protein degradation, collectively the proteins that comprise the 19S particle perform several proteasomal functions that include recognition of ubiquitylated substrates, cleavage of the polyubiquitin chain for ubiquitin recycling, control of access to the 20S proteolytic chamber, and substrate unfolding and subsequent translocation into the 20S core particle for degradation (Boehringer, *et al.*, 2012).

Mammalian proteasomes are associated with three DUBs: USP14, UCHL5 (UCH37) and RPN11 (POH1). UCHL5 and USP14 reside on the regulatory particle and remove ubiquitin from the substrate before substrate degradation whereas RPN11's activity is delayed until the proteasome is committed to degrading the substrate (Lee, *et al.*, 2010). The DUB activity of USP14 is known to be activated through its interaction with the proteasome complex.

The 26S proteasome product in this kit was prepared using the same protocol as described in Wang *et al.* (2007). The 26S proteasome DUB activity was removed through washing and treatment with ubiquitin–vinylsulphone (Ub–VS) which forms an adduct with the active site cysteine in DUBs of the thiol protease class (Lee, *et al.*, 2010).

References:

Boehringer J *et al.* (2012) Structural and functional characterization of Rpn12 identifies residues required for Rpn10 proteasome incorporation, *Biochem J* **448**, 55-65.

Deshpande KL *et al.* (1996) Cloning and characterization of cDNA encoding the rabbit tRNA-guanine transglycosylase 60-kilodalton subunit, *Arch Biochem Biophys* **326**, 1-7.

Kok K *et al.* (1993) A gene in the chromosomal region 3p21 with greatly reduced expression in lung cancer is similar to the gene for ubiquitin-activating enzyme, *Proc Natl Acad Sci USA* **90**, 6071-6075.

Komander D, Clague MJ and Urbe S (2009) Breaking the chains: structure and function of the deubiquitinases, *Nat Rev Mol Cell Biol* **10**, 550-563.

Lee BH *et al.* (2010) Enhancement of proteasome activity by a small-molecule inhibitor of USP14, *Nature* **467**, 179-184.

Reyes-Turcu FE, Ventii KH and Wilkinson KD (2009) Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes, *Ann Rev Biochem* **78**, 363-397.

Wang X *et al.* (2007) Mass spectrometric characterization of the affinity-purified human 26S proteasome complex, *Biochemistry* **46**, 3553-3565.

Limited Use License in respect of Cat. No. 65-1020-010

The Biotin AviTag™ technology is covered by U.S. Pat. Nos: 5,723,584; 5,874,239; 5,932,433; and 6,265,552 and includes any and all materials, methods, kits and related derivatives claimed by these patents. The purchase of the UBIQUIGENT's AviTagged products confers to the purchaser the limited right to use the AviTag™ technology for research use.

Commercial use of the AviTag™ technology to manufacture a commercial product, or use of the AviTag™ technology to facilitate or advance research which will be applied to the development of a commercial product requires a license from Avidity, LLC. Examples of Commercial use include, but are not limited to biosensors, diagnostics, therapeutic applications, proximity assays, and drug screening assays. Users desiring a commercial license should contact Avidity, LLC in the US @ 720-859-6111 or by email to Lansing@avidity.com.



www.ubiquigent.com
Dundee, Scotland, UK

ORDERS / SALES SUPPORT

International: +1-617-245-0020
US Toll-Free: 1-888-4E1E2E3 (1-888-431-3233)
Email: sales.support@ubiquigent.com

UK HQ and TECHNICAL SUPPORT

International: +44 (0) 1382 381147 (9AM-5PM UTC)
US/Canada: +1-617-245-0020 (9AM-5PM UTC)
Email: tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services.

© Ubiquigent 2014. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0